鼻ポリープ治療市場：薬剤クラス別、投与経路別、流通チャネル別、地域別

鼻ポリープ治療の世界市場は、2025年には36億5,000万米ドルと推定され、2032年には61億9,000万米ドルに達すると予測され、2025年から2032年にかけてCAGR7.8％で成長すると予測されています。

図.鼻ポリープ治療市場シェア（%）、2025年地域別

鼻ポリープ治療の世界市場は、慢性副鼻腔炎の世界の有病率の上昇により、著しい成長を遂げています。鼻ポリープは、鼻腔や副鼻腔の内壁に発生する非がん性の増殖です。通常、40～60歳の成人に発症し、喘息患者に多くみられます。遺伝的素因や環境アレルゲンなどの要因が開発に関与している可能性があります。鼻ポリープを治療せずに放置すると、鼻閉、嗅覚障害、顔面圧迫感や痛みを引き起こすことがあります。既存の治療法には、薬物療法、手術、経過観察などがあります。しかし、副作用の少ない新薬の登場により、市場の成長が見込まれています。

市場力学：

世界の鼻ポリープ治療市場を活性化する主な促進要因としては、慢性副鼻腔炎に罹患しやすい老年人口の増加、アレルギーを誘発する環境汚染レベルの上昇、低侵襲手術の採用増加などが挙げられます。しかし、手術費用の高さと新興国での認識不足が市場開拓の足かせとなっています。新規の標的薬治療薬や併用療法の開発にはビジネスチャンスがあります。また、ブロックバスター医薬品の特許切れが近いことから、バイオシミラー市場参入の余地もあります。

本調査の主な特徴

本レポートでは、世界の鼻ポリープ治療市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模および複合年間成長率（CAGR%）を掲載しています。

また、さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場の魅力的な投資提案マトリクスについて解説しています。

また市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する主要考察も提供しています。

企業ハイライト、製品ポートフォリオ、主要なハイライト、業績、戦略などのパラメータに基づいて、世界の鼻ポリープ治療市場における主要企業プロファイルを掲載しています。

本調査の対象となる主要企業には、サノフィ、メルク社、アストラゼネカ、リジェネロン社、ノバルティス社、オプティノース社、GSK plc.社、INTERSECT ENT, Inc.社、Sun Pharmaceutical Industries Ltd.社、Cipla社、Mylan N.V.社、Genentech社などが含まれます。

本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。

世界の鼻ポリープ治療市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学、規制、動向分析

• 市場力学
• 影響分析
• 主なハイライト
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• PORTERの分析
• 合併と買収のシナリオ
• 疫学

第4章 世界の鼻ポリープ治療市場、薬剤クラス別、2020年～2032年、（10億米ドル）

• コルチコステロイド
• インターロイキン阻害剤
• 抗ヒスタミン薬
• 抗生物質
• その他

第5章 世界の鼻ポリープ治療市場、投与経路別、2020年～2032年、（10億米ドル）

• 鼻腔
• 経口
• 非経口

第6章 世界の鼻ポリープ治療市場、流通チャネル別、2020年～2032年（10億米ドル）

• 病院薬局
• 小売薬局
• オンライン薬局

第7章 世界の鼻ポリープ治療市場、地域別、2020年～2032年、金額（10億米ドル）

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第8章 競合情勢

• Sanofi
• Merck & Co., Inc.
• AstraZeneca
• Regeneron Pharmaceuticals Inc.
• Novartis AG
• Optinose
• GSK plc.
• INTERSECT ENT, Inc.
• Sun Pharmaceutical Industries Ltd.
• Cipla
• Mylan N.V.
• Genentech

第9章 アナリストの推奨事項

• 機会
• アナリストの見解
• Coherent Opportunity Map

第10章 参考文献と調査手法

• 参考文献
• 調査手法
• 出版社について

Global Nasal Polyps Treatment Market is estimated to be valued at USD 3.65 Bn in 2025 and is expected to reach USD 6.19 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.8% from 2025 to 2032.

Figure. Nasal Polyps Treatment Market Share (%), By Region 2025

The global nasal polyps treatment market has been witnessing significant growth due to the rising prevalence of chronic sinusitis worldwide. Nasal polyps are non-cancerous growths that develop in the lining of the nasal cavities or sinuses. They usually affect adults aged between 40 and 60 years and are more common in people with asthma. Factors such as genetic predisposition and environmental allergens can contribute to their development. If left untreated, nasal polyps can cause nasal obstruction, loss of smell, and facial pressure or pain. The existing treatment options include drug therapies, surgery, and watchful monitoring. However, the market is expected to witness growth in the emergence of new drugs with fewer side effects.

Market Dynamics:

The key drivers fueling the global nasal polyps treatment market include the growing geriatric population's susceptibility to chronic sinusitis, rising environmental pollution levels triggering allergies, and increasing adoption of minimally invasive surgeries. However, the high cost of surgery and lack of awareness in developing nations are restricting market growth. Opportunities lie in the development of novel targeted drug therapeutics and combinational therapies. The upcoming patent expiries of blockbuster drugs also allow scope for biosimilar market entries.

Key Features of the Study:

This report provides in-depth analysis of the global nasal polyps treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global nasal polyps treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Sanofi, Merck & Co., Inc., AstraZeneca, Regeneron Pharmaceuticals Inc., Novartis AG, Optinose, GSK plc., INTERSECT ENT, Inc., Sun Pharmaceutical Industries Ltd., Cipla, Mylan N.V., and Genentech

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global nasal polyps treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Market Segmentation

• By Drug Class Insights (Revenue, USD Bn, 2019 - 2032)
  • Corticosteroids
  • Interleukin Inhibitors
  • Antihistamines
  • Antibiotics
  • Others
• By Route of Administration Insights (Revenue, USD Bn, 2019 - 2032)
  • Nasal
  • Oral
  • Parenteral
• By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Sanofi
  • Merck & Co., Inc.
  • AstraZeneca
  • Regeneron Pharmaceuticals Inc.
  • Novartis AG
  • Optinose
  • GSK plc.
  • INTERSECT ENT, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla
  • Mylan N.V.
  • Genentech

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Nasal Polyps Treatment Market, By Drug Class
  • Global Nasal Polyps Treatment Market, By Route of Administration
  • Global Nasal Polyps Treatment Market, By Distribution Channel
  • Global Nasal Polyps Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology

4. Global Nasal Polyps Treatment Market, By Drug Class, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Interleukin Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Antihistamines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Antibiotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Nasal Polyps Treatment Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Nasal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Nasal Polyps Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Nasal Polyps Treatment Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Regeneron Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Optinose
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• INTERSECT ENT, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cipla
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Genentech
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us